Advanced cancer treatment decisions and their patient-facing financial burdens: A thematic analysis

BACKGROUND: Most research about the high costs of cancer care has focused on characterizing and mitigating the financial hardship patients and families experience after cancer-directed therapy. Few studies have examined how these costs prospectively influence treatment decision-making. Even fewer address how costs impact decisions about symptom-directed therapies. We aim to describe how patient-facing costs of care influence decisions about cancer-directed and symptom-directed therapies for advanced cancer. MATERIALS AND METHODS: We analyzed semi-structured interviews with patients, care partners, clinicians, and health system leaders and clinical observations collected by investigators at 3 NCI-designated United States cancer centers between July 2019-May 2021. Two analysts conducted thematic analysis based on the Model of Financial Burden After Cancer Diagnosis. RESULTS: Analysis of 157 interviews and 92 observations identified 4 themes: (1) Insurance influenced treatment choice and location; (2) Medical costs influenced treatment choice, location, and timing; (3) Non-medical costs influenced treatment location and timing; and (4) Employment changes influenced treatment choice and timing. Patients and care partners emphasized costs of symptom-directed therapies; staff focused on costs of cancer-directed therapies. Patients and care partners described how employment influenced decisions about starting or continuing cancer-directed therapy, while staff noted how employment affected decisions about symptom-directed therapy. CONCLUSIONS: Patient-facing costs profoundly influence treatment decisions in advanced cancer care, but differences in perspective among patients, care partners, and clinicians can lead to oversights in treatment decision-making. Eliciting and incorporating patients' varied priorities into treatment decisions can minimize these oversights, better align treatment with goals of care, and reduce financial hardship.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-05-27
DOI
https://doi.org/10.1093/oncolo/oyag207
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advanced cancer treatment decisions and their patient-facing financial burdens: A thematic analysis

Rachel C Forcino, Garrett T. Wasp, Amber E. Barnato, Amanda N. Perry et al.
The Oncologist
Economic and Financial Impacts of Cancer
article

Advanced cancer treatment decisions and their patient-facing financial burdens: A thematic analysis

Rachel C Forcino, Garrett T. Wasp, Amber E. Barnato, Amanda N. Perry, Diya Mathur
article en

Abstract

BACKGROUND: Most research about the high costs of cancer care has focused on characterizing and mitigating the financial hardship patients and families experience after cancer-directed therapy. Few studies have examined how these costs prospectively influence treatment decision-making. Even fewer address how costs impact decisions about symptom-directed therapies. We aim to describe how patient-facing costs of care influence decisions about cancer-directed and symptom-directed therapies for advanced cancer. MATERIALS AND METHODS: We analyzed semi-structured interviews with patients, care partners, clinicians, and health system leaders and clinical observations collected by investigators at 3 NCI-designated United States cancer centers between July 2019-May 2021. Two analysts conducted thematic analysis based on the Model of Financial Burden After Cancer Diagnosis. RESULTS: Analysis of 157 interviews and 92 observations identified 4 themes: (1) Insurance influenced treatment choice and location; (2) Medical costs influenced treatment choice, location, and timing; (3) Non-medical costs influenced treatment location and timing; and (4) Employment changes influenced treatment choice and timing. Patients and care partners emphasized costs of symptom-directed therapies; staff focused on costs of cancer-directed therapies. Patients and care partners described how employment influenced decisions about starting or continuing cancer-directed therapy, while staff noted how employment affected decisions about symptom-directed therapy. CONCLUSIONS: Patient-facing costs profoundly influence treatment decisions in advanced cancer care, but differences in perspective among patients, care partners, and clinicians can lead to oversights in treatment decision-making. Eliciting and incorporating patients' varied priorities into treatment decisions can minimize these oversights, better align treatment with goals of care, and reduce financial hardship.

The Oncologist
Dartmouth College (US), Dartmouth Institute for Health Policy and Clinical Practice (US), University of Kansas (US), Dartmouth Psychiatric Research Center (US)
Openalex Percentile: Top 3%
Economic and Financial Impacts of Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.